GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk ...

The FDA has approved Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, just a few weeks after a rival shot from GSK became the first to be cleared in the US. Pfizer’s ...

The regulator is due to make a decision on Pfizer’s rival vaccine ... The approval marks the culmination of decades of effort in trying to develop an effective RSV vaccine after the virus ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

European Commission approves Pfizer's RSV vaccine for adults at increased risk of disease The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower ...

Major study shows that adults with respiratory syncytial virus-associated acute respiratory infection face a 2.7-fold higher ...

Pfizer and GlaxoSmithKline have agreed to end a lawsuit over alleged patent infringement involving their competing ...

SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals based on ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy wanes ...

GlaxoSmithKline (GSK) and Pfizer filed a stipulation to dismiss with prejudice GSK’s litigation in the United States District ...